Clinical trial
Study Evaluating PSI-697 in Patients With Scleritis
NCT00367692 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Terminated
Key facts
| NCT number | NCT00367692 |
|---|---|
| Title | Study Evaluating PSI-697 in Patients With Scleritis |
| Official title | An Exploratory, Double Blind, Placebo-controlled, Randomized, Single-dose, Cross-over, Proof of Mechanism Study of Orally Administered PSI-697 in Patients With Scleritis |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Scleritis |
| Intervention type | Drug |
| Interventions | PSI-697 |
| Enrollment | 12 |
| Start date | Sep 1, 2006 |
| Completion | Apr 1, 2007 |
| First posted | Aug 23, 2006 |
| Last update posted | Sep 9, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: